These findings underscore CK2B as a promising target for overcoming the exhaustion of effector CD8+ T cells, thereby enhancing the efficacy of αPD‐1 and adoptive cell therapies in NSCLC. Here, CSNK2B is linked to non-small cell lung carcinoma.